...
首页> 外文期刊>Advanced Science >Oligo Hyaluronan‐Coated Silica/Hydroxyapatite Degradable Nanoparticles for Targeted Cancer Treatment
【24h】

Oligo Hyaluronan‐Coated Silica/Hydroxyapatite Degradable Nanoparticles for Targeted Cancer Treatment

机译:Oligo透明质酸涂层二氧化硅/羟基磷灰石可降解纳米粒子可用于靶向癌症治疗

获取原文
           

摘要

Targeted drug delivery systems (TDDSs) provide a promising approach to overcome the side effect of traditional chemotherapy by specific tumor targeting and drug release. Hyaluronan (HA), as a selective CD44 targeting group, has been widely used in TDDSs for chemotherapy. However, different molecular weight HAs would demonstrate different binding ability to CD44, which may result in different therapeutic effects. Herein, a silica/hydroxyapatite (MSNs/HAP) hybrid carrier loaded with anticancer drug doxorubicin (DOX) (DOX@MSNs/HAP) is fabricated. HA and oligo HA (oHA) are coated onto the nanoparticles (HA‐DOX@MSNs/HAP, oHA‐DOX@MSNs/HAP), respectively, to investigate their performance in tumor targeting ability. oHA‐DOX@MSNs/HAP shows much higher efficiency cellular uptake and drug release in tumor regions due to more effective CD44 targeting of oHA. Thus, the anticancer effect of oHA‐DOX@MSNs/HAP is significantly enhanced compared to HA‐DOX@MSNs/HAP, as demonstrated in a tumor‐bearing mouse model. This study may enable the rational design of nanodrug systems for future tumor‐targeted chemotherapy.
机译:靶向药物递送系统(TDDSs)提供了一种有前途的方法,可以通过特定的肿瘤靶向和药物释放来克服传统化学疗法的副作用。透明质酸(HA)作为CD44的选择性靶向组,已被广泛用于TDDS化疗。但是,不同分子量的HAs将表现出与CD44的不同结合能力,这可能导致不同的治疗效果。在此,制备了负载有抗癌药阿霉素(DOX)(DOX @ MSNs / HAP)的二氧化硅/羟基磷灰石(MSNs / HAP)杂化载体。将HA和oligo HA(oHA)分别包被在纳米颗粒(HA-DOX @ MSNs / HAP,oHA-DOX @ MSNs / HAP)上,以研究其在肿瘤靶向能力中的表现。 oHA-DOX @ MSNs / HAP由于可更有效地靶向oHA的CD44,因此在肿瘤区域的细胞摄取和药物释放效率更高。因此,如荷瘤小鼠模型所示,与HA‐DOX @ MSNs / HAP相比,oHA‐DOX @ MSNs / HAP的抗癌作用显着增强。这项研究可能为未来肿瘤靶向化学疗法的纳米药物系统的合理设计提供了可能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号